BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS

被引：0
|
作者：
Fujii, R. K. [1 ]
Presa, J. [1 ]
Roberts, C. S. [2 ]
Gea, Y. [1 ]
Manfrin, D. F. [1 ]
Mould, J. [2 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer, New York, NY USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [41] Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older
    Frenck, Robert W., Jr.
    Fiquet, Anne
    Gurtman, Alejandra
    van Cleeff, Martin
    Davis, Matthew
    Rubino, John
    Smith, William
    Sundaraiyer, Vani
    Sidhu, Mohinder
    Emini, Emilio A.
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    VACCINE, 2016, 34 (30) : 3454 - 3462
  • [42] COST-EFFECTIVENESS OF 13-VALENT VERSUS 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE USE IN CROATIA NATIONAL VACCINATION PROGRAM
    Tichopad, A.
    Pecen, L.
    Roberts, C. S.
    Uglesic, L.
    Tesovic, G.
    Rogier, K.
    VALUE IN HEALTH, 2014, 17 (07) : A608 - A608
  • [43] A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 901 - 911
  • [44] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [45] Indirect impact of childhood 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian older adults: a Canadian Immunization Research Network (CIRN) retrospective observational study
    Nasreen, Sharifa
    Wang, Jun
    Marra, Fawziah
    Kwong, Jeffrey C.
    Mcgeer, Allison
    Sadarangani, Manish
    Wilson, Sarah E.
    Fadel, Shaza A.
    THORAX, 2024, 79 (09) : 861 - 869
  • [46] The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China
    Ronald Caldwell
    Craig S. Roberts
    Zhijie An
    Chieh-I Chen
    Bruce Wang
    BMC Infectious Diseases, 15
  • [47] The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China
    Caldwell, Ronald
    Roberts, Craig S.
    An, Zhijie
    Chen, Chieh-, I
    Wang, Bruce
    BMC INFECTIOUS DISEASES, 2015, 15
  • [48] THE HEALTH AND ECONOMIC IMPACT OF VACCINATION WITH 7-VALENT PNEUMOCOCCAL VACCINE (PCV7) DURING AN ANNUAL INFLUENZA EPIDEMIC AND INFLUENZA PANDEMIC IN CHINA
    Wang, B.
    Caldwell, R.
    Roberts, C. S.
    An, Z.
    Strutton, D. R.
    Chen, C., I
    VALUE IN HEALTH, 2014, 17 (03) : A275 - A275
  • [49] A TRANSMISSION-DYNAMIC MODEL TO PREDICT THE INDIRECT BENEFITS OF INFANT VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) TO OLDER POPULATIONS
    Snedecor, S.
    Strutton, D. R.
    Ciuryla, V
    Schwartz, E. J.
    Botteman, M.
    VALUE IN HEALTH, 2009, 12 (03) : A26 - A26
  • [50] Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake
    Naito, Toshio
    Matsuda, Naoto
    Tanei, Mika
    Watanabe, Yukiko
    Watanabe, Akira
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (7-8) : 450 - 453
12345